

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
MTSU-0001US

In Re Application Of: MIZUTANI, et al.

Serial No.
09/806,925Filing Date
4/6/01Examiner
UNKNOWNGroup Art Unit
UNKNOWNTitle: PREVENTATIVES OR REMEDIES FOR INFECTION, ANTI-ENDOTOXIN AGENTS, VACCINE
ADJUVANTS AND GROWTH PROMOTERS

RECEIVED

JUL 19 2001

TECH CENTER 1600/2900

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 50-0462 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

) on _____
(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on June 26, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Kevin J. Dunleavy

Typed or Printed Name of Person Mailing Correspondence

*This certificate may only be used if paying by deposit account.

Dated: June 26, 2001

Kevin J. Dunleavy, Esq.
Registration No. 32,024
KNOBLE & YOSHIDA, LLC
Eight Penn Center, Suite 1350
1628 John F. Kennedy Blvd.
Philadelphia, PA 19103

CC:

526 Rec'd PCT/PTO 02 JUL 2001
TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

In Re Application Of: MIZUTANI, et al.

Docket No.
MTSU-0001US

Serial No.
09/806,925

Filing Date
4/6/01

Examiner
UNKNOWN

Group Art Unit
UNKNOWN

Title: PREVENTATIVES OR REMEDIES FOR INFECTION, ANTI-ENDOTOXIN AGENTS, VACCINE
ADJUVANTS AND GROWTH PROMOTERS

RECEIVED

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

JUL 19 2001
TECH CENTER 1600/2900

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
 2. a Notice of Allowance under 37 CFR 1.311,
- whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).